Mass High Tech
ACUITYBIO CORP
Is this your company?
Update it or Add a Logo
Logos place your company at the
top of the search results!
About:
AcuityBio has developed a unique, and simple to use, drug-eluting implant that reduces the incidence of locoregional lung cancer recurrence by locally delivering therapeutic levels of drug to the site of disease for over several months.
Headlines from Mass High Tech about ACUITYBIO CORP
Print this Listing
Product Information
| Industry Classification | Biopharma/Biotechnology |
| Primary Business Focus | Biotechnology - Non-Pharmaceutical |
| Other Business Offering | Biotechnology - Pharmaceutical |
Details
| Year Established | 2008 |
| Ownership Type | Private |
| Venture Funding | Subscriber access only |
| Anticipated Workforce Changes | Subscriber access only |
| Foreign Distribution | Subscriber access only |
Contacts
| Mark Grinstaff | Co-Founder | |||
| Jesse Wolinsky | Co-Founder | |||
| Jay Schwartz | CEO | email available to subscribers |
* Downloads will not contain Personnel E-mail addresses
Search the Directory
Company Overview
| Focus | Biotechnology - Non-Pharmaceutical |
| Location | Newton, MA |
| Website | http://www.acuitybio.com |
| Revenue | Subscriber access only |
Contact Information
| Address | 200 Upland Rd Newton, MA, 02460 |
| Phone | 617-515-9671 |
| Subscriber access only | |
| Website | www.acuitybio.com |
New England Tech Directory
| Browse
| Subscribe
| Advertise
| Networking
| About Us
| Search
| 
RSS Feeds
| 
| Directory License
| Update User Info
| Directory Privacy Policy
| Logout
© 2012 American City Business Journals, Inc. and its licensors. All rights reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of bizjournals.
Affiliate publications: ACBJ.com, Boston Business Journal, Bizjournals.com, Portfolio.com, Wired.com
Use of and/or registration on any portion of this site constitutes acceptance of our User Agreement and Privacy Policy. About our ads.